Latest news
Adlai Nortye Announces First-in-Class AN4035 Cleared for Phase I Clinical Development as First Pan-RAS(ON) ADC to Enter the Clinic - Quiver QuantitativeQuiver Quantitative · Mon, 03 Aug 2026 11:15:00 GMTInsilico Medicine Receives FDA Fast Track Designation for ISM6331, the AI-driven Pan-TEAD Inhibitor, in Advanced Mesothelioma - Insilico MedicineInsilico Medicine · Tue, 28 Jul 2026 07:00:00 GMT